Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteasomal ubiquitin receptor ADRM1 (Rpn13) is a non-ATPase subunit of the 19S regulatory particle in the 26S proteasome, essential for intracellular protein degradation. Rpn13 functions as a ubiquitin receptor, recognizing and binding ubiquitinated substrates and facilitating their recruitment and processing by the proteasome. It contains a conserved N-terminal Pru domain for ubiquitin binding and interacts with other proteasomal components, notably the deubiquitinating enzyme UCHL5/Uch37. Rpn13 is critical for protein homeostasis and targeted degradation of misfolded or regulatory proteins, and its dysfunction or inhibition is linked to diseases such as cancer. Rpn13 is a validated therapeutic target with small molecule inhibitors in development for oncology indications.
Inhibition of Rpn13 prevents docking of ubiquitinated proteins for degradation Inhibitors may cause accumulation of misfolded/damaged proteins, leading to cellular stress and apoptosis, especially in cancer cells
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasomal ubiquitin receptor ADRM1 (Rpn13).